argenx SE (ARGX)

358,41 -7,79 (-2,13%) Al cierre: 04:00PM EDT

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 1148

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.	CEO & Executive Director	1,29M	N/A	1972
Mr. Karl Gubitz	Chief Financial Officer	843,26k	N/A	1970
Ms. Karen Massey	Chief Operating Officer	1,42M	N/A	1979
Mr. Filip Borgions	VP & Global Head of Technical Operations	N/A	N/A	N/A
Mr. Peter Ulrichts	Chief Scientific Officer	N/A	N/A	1980
Ms. Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Ms. Malini Moorthy	General Counsel	N/A	N/A	1970
Mr. Arjen Lemmen M.Sc.	Vice President of Corporate Development & Strategy	N/A	N/A	1985
Mr. Marc Schorpion	Global Head of Human Resources	N/A	N/A	1959
Ms. Andria Wilk	Global Head of Quality	N/A	N/A	1974

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de argenx SE, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 4; Tablero: 2; Derechos de los accionistas: 3; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.